553 related articles for article (PubMed ID: 31727290)
1. Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection: JACC Review Topic of the Week.
Cherney DZ; Odutayo A; Aronson R; Ezekowitz J; Parker JD
J Am Coll Cardiol; 2019 Nov; 74(20):2511-2524. PubMed ID: 31727290
[TBL] [Abstract][Full Text] [Related]
2. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
[TBL] [Abstract][Full Text] [Related]
3. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
Mima A
J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
[TBL] [Abstract][Full Text] [Related]
4. Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease.
Liu H; Sridhar VS; Boulet J; Dharia A; Khan A; Lawler PR; Cherney DZI
Metabolism; 2022 Jan; 126():154918. PubMed ID: 34699838
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
6. Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus: A Need to Rethink.
Sattar N; McGuire DK
Circulation; 2018 Jul; 138(1):7-9. PubMed ID: 29967228
[No Abstract] [Full Text] [Related]
7. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence.
Davidson JA
Postgrad Med; 2019 May; 131(4):251-260. PubMed ID: 30929540
[TBL] [Abstract][Full Text] [Related]
8. SGLT2 inhibition and kidney protection.
Nespoux J; Vallon V
Clin Sci (Lond); 2018 Jun; 132(12):1329-1339. PubMed ID: 29954951
[TBL] [Abstract][Full Text] [Related]
9. Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control.
Takata T; Isomoto H
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922132
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
11. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
Packer M
Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
[TBL] [Abstract][Full Text] [Related]
12. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838
[TBL] [Abstract][Full Text] [Related]
13. Sodium glucose cotransporter-2 inhibitors protect the cardiorenal axis: Update on recent mechanistic insights related to kidney physiology.
van Ruiten CC; Hesp AC; van Raalte DH
Eur J Intern Med; 2022 Jun; 100():13-20. PubMed ID: 35414444
[TBL] [Abstract][Full Text] [Related]
14. Kidney and cardiovascular protection with SGLT2 inhibitors: lessons from cardiovascular outcome trials and CREDENCE.
O'Hara DV; Neuen BL; Jardine MJ
J Nephrol; 2020 Oct; 33(5):977-983. PubMed ID: 32725496
[TBL] [Abstract][Full Text] [Related]
15. Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors.
Prandi FR; Barone L; Lecis D; Belli M; Sergi D; Milite M; Lerakis S; Romeo F; Barillà F
Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291558
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes.
Giugliano D; Longo M; Scappaticcio L; Caruso P; Esposito K
Cardiovasc Diabetol; 2021 Jan; 20(1):17. PubMed ID: 33430860
[TBL] [Abstract][Full Text] [Related]
17. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
Cruz JE; Ahuja T; Bridgeman MB
Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?
Neuen BL; Jardine MJ; Perkovic V
Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i48-i55. PubMed ID: 32003833
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
Alicic RZ; Johnson EJ; Tuttle KR
Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms for Cardiorenal Protection of SGLT-2 Inhibitors.
Georgianos PI; Vaios V; Dounousi E; Salmas M; Eleftheriadis T; Liakopoulos V
Curr Pharm Des; 2021; 27(8):1043-1050. PubMed ID: 33463454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
